Download Citation
Article Source:
Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study
Wolf C,
Sidhu J,
Otoul C,
Morris DL,
Cnops J,
et al.
(2013)
Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study.
PLOS ONE 8(3): e58438.
https://doi.org/10.1371/journal.pone.0058438